Targeting HMGB1/TLR4 signaling as a novel approach to treatment of cerebral ischemia

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 3, 2010, Pages 1081-1091

  Yang, Qing Wu ^a   Xiang, Jing ^a   Zhou, Yu ^a   Zhong, Qi ^a   Li, Jing Cheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HMGB1; Inflammation; Ischemia; Neuroprotection; Review; TLR4

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; LIGAND; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR 4;

ANIMAL; BIOLOGICAL MODEL; BRAIN; BRAIN ISCHEMIA; DRUG ANTAGONISM; HUMAN; ISCHEMIC PRECONDITIONING; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; BRAIN ISCHEMIA; HMGB1 PROTEIN; HUMANS; ISCHEMIC PRECONDITIONING; LIGANDS; MODELS, NEUROLOGICAL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 77956622706     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s119     Document Type: Article

References (87)

1. T. Takano, G.F. Tian, W. Peng, N. Lou, D. Lovatt, A.J. Hansen, KA. Kasischke and M. Nedergaard: Cortical spreading depression causes and coincides with tissue hypoxia. Nat Neurosci 10, 754-762 (2007) (Pubitemid 46828508)
2. C.X. Cao, Q.W. Yang, F.L. Lv, J. Cui, H.B. Fu, and J.Z. Wang: Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Commun 353, 509-514 (2007) (Pubitemid 46023466)
3. J.R. Caso, J.M. Pradillo, O. Hurtado, P. Lorenzo, MA. Moro and Lizasoain I: Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 115, 1599-1608 (2007) (Pubitemid 46648645)
4. Q.W. Yang, J.C. Li, FL. Lu, A.Q. Wen, J. Xiang, L.L. Zhang, Z.Y. Huang and J.Z. Wang: Upregulated expression of Toll-like receptor 4 in monocytes correlates with severity of acute cerebral infarction. J Cereb Blood Flow Metab 28, 1588-1596 (2008)
5. G. Faraco, S. Fossati, M.E. Bianchi, M. Patrone, M. Pedrazzi, B. Sparatore, F. Moroni and A. Chiarugi: High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 103, 590-603 (2007) (Pubitemid 47498027)
6. J.B. Kim, C.M. Lim, Y.M. Yu and J.K. Lee: Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 86, 1125-1131 (2008)
7. J.B. Kim, J. Sig Choi, Y.M. Yu, K. Nam, C.S. Piao, S.W. Kim, M.H. Lee, P.L. Han, J.S. Park and J.K. Lee: HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26, 6413-6421 (2006) (Pubitemid 44318322)
8. S. Muhammad, W. Barakat, S. Stoyanov, S. Murikinati, H. Yang, K.J. Tracey, M. Bendszus, G. Rossetti, P.P. Nawroth, A. Bierhaus and M. Schwaninger: The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 28, 12023-12031 (2008)
9. J. Qiu, M. Nishimura, Y. Wang, J.R. Sims, S. Qiu, S.I. Savitz, S. Salomone and M.A. Moskowitz: Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 28, 927-938 (2008) (Pubitemid 351589627)
10. G.H. Goodwin, C. Sanders and E.W. Johns: A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 38: 14-19 (1973)
11. J.O. Thomas: Hmg1 and 2: Architectural DNA-binding proteins. Biochem Soc Trans 29, 395-401 (2001)
12. M. Bustin: Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 26, 152-153 (2001)
13. T. Haas, J. Metzger, F. Schmitz, A. Heit, T. Muller, E. Latz and H. Wagner: The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 28, 315-323 (2008) (Pubitemid 351335308)
14. M. Yu, H. Wang, A. Ding, D.T. Golenbock, E. Latz, C.J. Czura, M.J. Fenton, K.J. Tracey and H. Yang: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26, 174-179 (2006) (Pubitemid 44162504)
15. M.T. Lotze and K.J. Tracey: High-mobility group box 1 protein (HMGB-1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5, 331-342 (2005) (Pubitemid 40516158)
16. J.S. Park, D. Svetkauskaite, Q. He, J.Y. Kim, D. Strassheim, A. Ishizaka and E. Abraham: Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279, 7370-7377 (2004) (Pubitemid 38294612)
17. M.E. Bianchi and A.A. Manfredi: High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220, 35-46 (2007) (Pubitemid 350045574)
18. H. Rauvala and A. Rouhiainen: Rage as a receptor of HMGB-1 (amphoterin): Roles in health and disease. Curr Mol Med 7, 725-734 (2007)
19. M.E. Bianchi: Significant (re)location: How to use chromatin and/or abundant proteins as messages of life and death. Trends Cell Biol 14, 287-293 (2004) (Pubitemid 38798177)
20. S. Yamada and I. Maruyama: HMGB-1, a novel inflammatory cytokine. Clin Chim Acta 375, 36-42 (2007)
21. K. Liu, S. Mori, H.K. Takahashi, Y. Tomono, H. Wake, T. Kanke, Y. Sato, N. Hiraga, N. Adachi, T. Yoshino and M. Nishibori: Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21, 3904-3916 (2007) (Pubitemid 350232348)
22. S. Mori, K. Liu, H.K. Takahashi and M. Nishibori: Therapeutic effect of anti-nucleokine monoclonal antibody on ischemic brain infarction. Yakugaku Zasshi 129, 25-31 (2009)
23. M.A. van Zoelen, H. Yang, S. Florquin, J.C. Meijers, S. Akira, B. Arnold, P.P. Nawroth, A. Bierhaus, K.J. Tracey and T. Poll: Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31, 280-284 (2009)
24. B. Kruger, S. Krick, N. Dhillon, S.M. Lerner, S. Ames, J.S. Bromberg, M. Lin, L. Walsh, J. Vella, M. Fischereder, B.K. Kramer, R.B. Colvin, P.S. Heeger, B.T. Murphy and B. Schroppel: Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A 106, 3390-3395 (2009)
25. M.D. Nguyen, J.P. Julien and S. Rivest: Innate immunity: Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 3, 216-227 (2002) (Pubitemid 135706591)
26. C. Zuany-Amorim, J. Hastewell and C. Walker: Tolllike receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 1, 797-807 (2002) (Pubitemid 37361563)
27. M. Bustin and N.K. Neihart: Antibodies against chromosomal HMG proteins stain the cytoplasm of mammalian cells. Cell 16, 181-189 (1979) (Pubitemid 9097687)
28. T. Bonaldi, F. Talamo, P. Scaffidi, D. Ferrera, A. Porto, A. Bachi, A. Rubartelli, A. Agresti and M.E. Bianchi: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22, 5551-5560 (2003) (Pubitemid 37279964)
29. S. Gardella, C. Andrei, D. Ferrera, L.V. Lotti, M.R. Torrisi, M.E. Bianchi and A. Rubartelli: The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3, 995-1001 (2002) (Pubitemid 35256475)
30. W. Parrish and L. Ulloa: High-mobility group box-1 isoforms as potential therapeutic targets in sepsis. Methods Mol Biol 361, 145-162 (2007) (Pubitemid 350183205)
31. H. Yang, H. Wang, C.J. Czura and K.J. Tracey: The cytokine activity of HMGB1. J Leukoc Biol 78, 1-8 (2005) (Pubitemid 40979937)
32. H. Wang, O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, A. Frazier, H. Yang, S. Ivanova, L. Borovikova, K.R. Manogue, E. Faist, E. Abraham, J. Andersson, U. Andersson, P.E. Molina, N.N. Abumrad, A. Sama and K.J. Tracey: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999) (Pubitemid 29329996)
33. C. Semino, G. Angelini, A. Poggi and A. Rubartelli: NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106, 609-616 (2005) (Pubitemid 40981258)
34. D. Agnello, H. Wang, H. Yang, K.J. Tracey and P. Ghezzi: HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine 18, 231-236 (2002) (Pubitemid 34775431)
35. K.A. O'Connor, M.K. Hansen, C. Rachal Pugh, M.M. Deak, J.C. Biedenkapp, E.D. Milligan, J.D. Johnson, H. Wang, S.F. Maier, K.J. Tracey and L.R. Watkins: Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine 24, 254-265 (2003) (Pubitemid 37373661)
36. M. Passalacqua, M. Patrone, G.B. Picotti, M. Del Rio, B. Sparatore, E. Melloni and S. Pontremoli: Stimulated astrocytes release high-mobility group 1 protein, an inducer of LAN-5 neuroblastoma cell differentiation. Neuroscience 82, 1021-1028 (1998) (Pubitemid 27502047)
37. S. Fossati and A. Chiarugi: Relevance of high-mobility group protein box 1 to neurodegeneration. Int Rev Neurobiol 82, 137-148 (2007)
38. H. Rauvala and R. Pihlarskai: Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 262, 16625-16635 (1987)
39. J. Merenmies, R. Pihlaskari, J. Laitinen, J. Wartiovaara and H. Rauvala: 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 266, 16722-16729 (1991) (Pubitemid 21907859)
40. S. Guazzi, A. Strangio, A.T. Franzi and M.E. Bianchi: HMGB1, an architectural chromatin protein and extracellular signalling factor, has a spatially and temporally restricted expression pattern in mouse brain. Gene Expr Patterns 3, 29-33 (2003) (Pubitemid 36356037)
41. Q.W. Yang, J.Z. Wang, J.C. Li, Y. Zhou, Q. Zhong, F.L. Lu, J. Xiang: High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab 30, 243-254 (2010)
42. C.C. Bowman, A. Rasley, S.L. Tranguch and I. Marriott: Cultured astrocytes express toll-like receptors for bacterial products. Glia 43, 281-291 (2003) (Pubitemid 37047684)
43. S. Lehnardt, C. Lachance, S. Patrizi, S. Lefebvre, P.L. Follett, F.E. Jensen, P.A. Rosenberg, J.J. Volpe and T. Vartanian: The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 22, 2478-2486 (2002) (Pubitemid 37465796)
44. S. Lehnardt, L. Massillon, P. Follett, F.E. Jensen, R. Ratan, P.A. Rosenberg, J.J. Volpe and T. Vartanian: Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 100, 8514-8519 (2003) (Pubitemid 36842576)
45. M. Lafon, F. Megret, M. Lafage and C. Prehaud: The innate immune facet of brain: The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J Mol Neurosci 29, 185-194 (2006) (Pubitemid 44684494)
46. Y. Ma, J. Li, I. Chiu, Y. Wang, J.A. Sloane, J. Lu, B. Kosaras, R.L. Sidman, J.J. Volpe and T. Vartanian: Tolllike receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. J Cell Biol 175, 209-215 (2006) (Pubitemid 44631415)
47. S.C. Tang, T.V. Arumugam, X. Xu, A. Cheng, M.R. Mughal, D.G. Jo, J.D. Lathia, D.A. Siler, S. Chigurupati, X. Ouyang, T. Magnus, S. Camandola and M.P. Mattson: Pivotal role for neuronal toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 104, 13798-13803 (2007) (Pubitemid 350003400)
48. S.C. Tang, J.D. Lathia, P.K. Selvaraj, D.G. Jo, M.R. Mughal, A. Cheng, D.A. Siler, W.R. Markesbery, T.V. Arumugam and M.P. Mattson: Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol 213, 114-121 (2008)
49. S.L. Stevens, T.M. Ciesielski, B.J. Marsh, T. Yang, D.S. Homen, J.L. Boule, N.S. Lessov, R.P. Simon and M.P. Stenzel-Poore: Toll-like receptor 9: A new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab 28, 1040-1047 (2008) (Pubitemid 351589642)
50. R.N. Aravalli, P.K. Peterson and J.R. Lokensgard: Tolllike receptors in defense and damage of the central nervous system. J Neuroimmune Pharmacol 2, 297-312 (2007)
51. C. Prehaud, F. Megret, M. Lafage and M. Lafon: Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J Virol 79, 12893-12904 (2005) (Pubitemid 41433208)
52. M. Bsibsi, R. Ravid, D. Gveric and J.M. van Noort: Broad expression of toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 61, 1013-1021 (2002) (Pubitemid 35278723)
53. Y.C. Lu, W.C. Yeh and P.S. Ohashi: LPS/TLR4 signal transduction pathway. Cytokine 42, 145-151 (2008)
54. T.V. Arumugam, E. Okun, S.C. Tang, J. Thundyil, S.M. Taylor and T.M. Woodruff: Toll-like receptors in ischemia-reperfusion injury. Shock 32, 4-16 (2009)
55. A. Tsung, R. Sahai, H. Tanaka, A. Nakao, M.P. Fink, M.T. Lotze, H. Yang, J. Li, K.J. Tracey, D.A. Geller and T.R. Billiar: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201, 1135-1143 (2005) (Pubitemid 40524681)
56. J.S. Park, J. Arcaroli, H.K. Yum, H. Yang, H. Wang, K.Y. Yang, K.H. Choe, D. Strassheim, T.M. Pitts, K.J. Tracey and E. Abraham: Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284, C870-879 (2003) (Pubitemid 36336943)
57. J.S. Park, F. Gamboni-Robertson, Q. He, D. Svetkauskaite, J.Y. Kim, D. Strassheim, J.W. Sohn, S. Yamada, I. Maruyama, A. Banerjee, A. Ishizaka and E. Abraham: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290, C917-924 (2006)
58. S. Akira and K. Takeda: Toll-like receptor signalling. Nat Rev Immunol 4, 499-511 (2004) (Pubitemid 38931765)
59. M. Karin and Y. Ben-Neriah: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18, 621-663 (2000) (Pubitemid 30365393)
60. Y. Sha, J. Zmijewski, Z. Xu and E. Abraham: HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 180, 2531-2537 (2008)
61. J.H. Youn, Y.J. Oh, E.S. Kim, J.E. Choi and J.S. Shin: High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 180, 5067-5074 (2008)
62. F. Hua, J. Wang, I. Sayeed, T. Ishrat, F. Atif and D.G. Stein: The TRIF-dependent signaling pathway is not required for acute cerebral ischemia/reperfusion injury in mice. Biochem Biophys Res Commun 390, 678-683 (2009)
63. R.S. Goldstein, M. Gallowitsch-Puerta, L. Yang, M. Rosas-Ballina, J.M. Huston, C.J. Czura, D.C. Lee, M.F. Ward, A.N. Bruchfeld, H. Wang, M.L. Lesser, A.L. Church, A.H. Litroff, A.E. Sama and K.J. Tracey: Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25, 571-574 (2006) (Pubitemid 44297016)
64. U. Kilic, E. Kilic, C.M. Matter, C.L. Bassetti and D.M. Hermann: TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. Neurobiol Dis 31, 33-40 (2008)
65. J.R. Caso, J.M. Pradillo, O. Hurtado, J.C. Leza, M.A. Moro and I. Lizasoain: Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke 39, 1314-1320 (2008) (Pubitemid 351440707)
66. J.M. Pradillo, D. Fernandez-Lopez, I. Garcia-Yebenes, M. Sobrado, O. Hurtado, M.A. Moro and I. Lizasoain: Tolllike receptor 4 is involved in neuroprotection afforded by ischemic preconditioning. J Neurochem 109, 287-294 (2009)
67. B.J. Marsh, R.L. Williams-Karnesky and M.P. Stenzel-Poore: Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 158, 1007-1020 (2009)
68. T.P. Obrenovitch: Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev 88, 211-247 (2008)
69. H.L. Rosenzweig, M. Minami, N.S. Lessov, S.C. Coste, S.L. Stevens, D.C. Henshall, R. Meller, R.P. Simon and M.P. Stenzel-Poore: Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance. J Cereb Blood Flow Metab 27, 1663-1674 (2007) (Pubitemid 47476093)
70. L. Ulloa: The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 4, 673-684 (2005) (Pubitemid 41149761)
71. L. Ulloa and D. Messmer: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17, 189-201 (2006) (Pubitemid 43949075)
72. L. Ulloa and K.J. Tracey: The "Cytokine profile,": A code for sepsis. Trends Mol Med 11, 56-63 (2005)
73. H. Yang, M. Ochani, J. Li, X. Qiang, M. Tanovic, H.E. Harris, S.M. Susarla, L. Ulloa, H. Wang, R. DiRaimo, C.J. Czura, H. Wang, J. Roth, H.S. Warren, M.P. Fink, M.J. Fenton, U. Andersson and K.J. Tracey: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101, 296-301 (2004) (Pubitemid 38084244)
74. G. Sitia G, M. Iannacone, S. Müller, M.E. Bianchi, L.G. Guidotti: Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 81, 100-107 (2007) (Pubitemid 46021258)
75. R. Kokkola, J. Li, E. Sundberg, A.C. Aveberger, K. Palmblad, H. Yang, K.J. Tracey, U. Andersson and H.E. Harris: Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 48, 2052-2058 (2003) (Pubitemid 36828701)
76. J.R. Klune, T.R. Billiar and A: Tsung. Hmgb1 preconditioning: Therapeutic application for a danger signal? J Leukoc Biol 83, 558-563 (2008) (Pubitemid 351966865)
77. K. Izuishi, A. Tsung, G. Jeyabalan, N.D. Critchlow, J. Li, K.J. Tracey, R.A. Demarco, M.T. Lotze, M.P. Fink, D.A. Geller and T.R. Billiar: Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol 176, 7154-7158 (2006) (Pubitemid 43849015)
78. Q. Yang, Q. Zhong, C. Cao, J. Li, F. Lu and J. Wang: Anti-Toll Like Receptor 4 monoclonal antibody attenuates cerebral ischemia-reperfusion injury. Cerebrovasc Dis 26, 217-218 (2008)
79. K. Tasaki, C.A. Ruetzler, T. Ohtsuki, D. Martin, H. Nawashiro and J.M. Hallenbeck: Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 748, 267-270 (1997) (Pubitemid 27094913)
80. H.L. Rosenzweig, N.S. Lessov, D.C. Henshall, M. Minami, R.P. Simon and M.P. Stenzel-Poore: Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice. Stroke 35, 2576-2581 (2004) (Pubitemid 39458420)
81. E.J. Hickey, X. You, V. Kaimaktchiev, M. Stenzel-Poore and R.M. Ungerleider: Lipopolysaccharide preconditioning induces robust protection against brain injury resulting from deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg 133, 1588-1596 (2007) (Pubitemid 46802584)
82. A. Kunz, L. Park, T. Abe, E.F. Gallo, J. Anrather, P. Zhou and C. Iadecola: Neurovascular protection by ischemic tolerance: role of nitric oxide and reactive oxygen species. J Neurosci 27, 7083-7093 (2007) (Pubitemid 47037566)
83. R. Bordet, D. Deplanque, P. Maboudou, F. Puisieux, Q. Pu, E. Robin, A. Martin, M. Bastide, D. Leys, M. Lhermitte, B. Dupuis: Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide- induced brain ischemic tolerance. J Cereb Blood Flow Metab 20, 1190-1196 (2000) (Pubitemid 30636754)
84. K. Kikuchi, K. Kawahara, K.K. Biswas, T. Ito, S. Tancharoen, Y. Morimoto, F. Matsuda, Y. Oyama, K. Takenouchi, N. Miura, N. Arimura, Y. Nawa, X. Meng, B. Shrestha, S. Arimura, M. Iwata, K. Mera, H. Sameshima, Y. Ohno, R. Maenosono, Y. Yoshida, Y. Tajima, H. Uchikado, T. Kuramoto, K. Nakayama, M. Shigemori, T. Hashiguchi and I. Maruyama: Minocycline attenuates both OGD-induced HMGB1 release and HMGB1-induced cell death in ischemic neuronal injury in PC12 cells. Biochem Biophys Res Commun 385, 132-136 (2009)
85. K. Hayakawa, K. Mishima, M. Nozako, M. Hazekawa, S. Mishima, M. Fujioka, K. Orito, N. Egashira, K. Iwasaki abd M. Fujiwara: Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 39, 951-958 (2008) (Pubitemid 351619558)
86. K. Kikuchi, K. Kawahara, S. Tancharoen, F. Matsuda, Y. Morimoto, T. Ito, K.K. Biswas, K. Takenouchi, N. Miura, Y. Oyama, Y. Nawa, N. Arimura, M. Iwata, Y. Tajima, T. Kuramoto, K. Nakayama, M. Shigemori, Y. Yoshida, T. Hashiguchi and I. Maruyama: The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther 329, 865-874 (2009)
87. A.E. Medvedev, A. Lentschat, L.M. Wahl, D.T. Golenbock and S.N. Vogel: Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 169, 5209-5216 (2002) (Pubitemid 35217192)